JP5814793B2 - ブロックコポリマーおよびその使用 - Google Patents

ブロックコポリマーおよびその使用 Download PDF

Info

Publication number
JP5814793B2
JP5814793B2 JP2011538669A JP2011538669A JP5814793B2 JP 5814793 B2 JP5814793 B2 JP 5814793B2 JP 2011538669 A JP2011538669 A JP 2011538669A JP 2011538669 A JP2011538669 A JP 2011538669A JP 5814793 B2 JP5814793 B2 JP 5814793B2
Authority
JP
Japan
Prior art keywords
poly
block
drug
peg
block copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011538669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509983A5 (enExample
JP2012509983A (ja
Inventor
ディクソン，ジェームズ，ブランドン
ハベル，ジェフリー，エー．
オニール，コンリン，ピー．
シュワルツ，メロディ
ブレットー，ディアナ
Original Assignee
エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル）
エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル）, エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル） filed Critical エコール ポリテクニク フェデラル ド ローザンヌ（エーペーエフエル）
Publication of JP2012509983A publication Critical patent/JP2012509983A/ja
Publication of JP2012509983A5 publication Critical patent/JP2012509983A5/ja
Application granted granted Critical
Publication of JP5814793B2 publication Critical patent/JP5814793B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3344—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing oxygen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G75/00—Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
    • C08G75/02—Polythioethers
    • C08G75/06—Polythioethers from cyclic thioethers
    • C08G75/08—Polythioethers from cyclic thioethers from thiiranes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/008—Supramolecular polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/05—Polymer mixtures characterised by other features containing polymer components which can react with one another
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L81/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing sulfur with or without nitrogen, oxygen or carbon only; Compositions of polysulfones; Compositions of derivatives of such polymers
    • C08L81/02—Polythioethers; Polythioether-ethers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011538669A 2008-11-25 2009-11-24 ブロックコポリマーおよびその使用 Active JP5814793B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11789208P 2008-11-25 2008-11-25
US61/117,892 2008-11-25
PCT/US2009/065693 WO2010068432A1 (en) 2008-11-25 2009-11-24 Block copolymers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014217197A Division JP5995939B2 (ja) 2008-11-25 2014-10-24 ブロックコポリマーおよびその使用

Publications (3)

Publication Number Publication Date
JP2012509983A JP2012509983A (ja) 2012-04-26
JP2012509983A5 JP2012509983A5 (enExample) 2013-01-17
JP5814793B2 true JP5814793B2 (ja) 2015-11-17

Family

ID=42243027

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011538669A Active JP5814793B2 (ja) 2008-11-25 2009-11-24 ブロックコポリマーおよびその使用
JP2014217197A Active JP5995939B2 (ja) 2008-11-25 2014-10-24 ブロックコポリマーおよびその使用
JP2016100375A Active JP6409020B2 (ja) 2008-11-25 2016-05-19 ブロックコポリマーおよびその使用
JP2018119659A Active JP6641423B2 (ja) 2008-11-25 2018-06-25 ブロックコポリマーおよびその使用
JP2019238237A Pending JP2020073678A (ja) 2008-11-25 2019-12-27 ブロックコポリマーおよびその使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2014217197A Active JP5995939B2 (ja) 2008-11-25 2014-10-24 ブロックコポリマーおよびその使用
JP2016100375A Active JP6409020B2 (ja) 2008-11-25 2016-05-19 ブロックコポリマーおよびその使用
JP2018119659A Active JP6641423B2 (ja) 2008-11-25 2018-06-25 ブロックコポリマーおよびその使用
JP2019238237A Pending JP2020073678A (ja) 2008-11-25 2019-12-27 ブロックコポリマーおよびその使用

Country Status (4)

Country Link
US (5) US9271929B2 (enExample)
EP (1) EP2356228B1 (enExample)
JP (5) JP5814793B2 (enExample)
WO (1) WO2010068432A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
EP2356228B1 (en) * 2008-11-25 2023-05-03 École Polytechnique Fédérale de Lausanne (EPFL) Block copolymers and uses thereof
CN103002982B (zh) * 2010-05-21 2016-06-08 国立研究开发法人科学技术振兴机构 物质内包囊泡及其制造方法
CN102971002B (zh) * 2010-07-09 2019-04-05 国立大学法人东京大学 核酸递送用组合物及载体组合物、使用其的药物组合物以及核酸递送方法
US9718921B2 (en) 2013-02-26 2017-08-01 The Regents Of The University Of California Amphiphilic derivatives of thioether containing block copolypeptides
WO2015013510A1 (en) * 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
WO2015058141A1 (en) * 2013-10-18 2015-04-23 Virginia Tech Intellectual Properties, Inc. Nucleobase-containing monomers and copolymers
WO2015070080A2 (en) * 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Nucleic acid nanostructures for in vivo agent delivery
WO2016154120A1 (en) 2015-03-20 2016-09-29 The Regents Of The University Of California Polypeptides, peptides, and proteins functionalized by alkylation of thioether groups via ring-opening reactions
US10456452B2 (en) * 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
EP3124495A1 (en) 2015-07-31 2017-02-01 Centre National de la Recherche Scientifique (C.N.R.S.) Derivatives of elastin-like polypeptides and uses thereof
EP3426598B1 (en) 2016-03-11 2021-07-28 Children's Medical Center Corporation Nucleic acid nanoswitch catenanes
EP3448872A4 (en) 2016-04-27 2019-12-11 The Regents of the University of California PREPARATION OF FUNCTIONAL HOMOCYSTEINRESTES IN POLYPEPTIDES AND PEPTIDES
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
US11034786B2 (en) 2016-06-16 2021-06-15 Lg Chem, Ltd. Amphiphilic triblock polymer
WO2018022457A1 (en) * 2016-07-29 2018-02-01 The Regents Of The University Of California Accelerated healing by injectable multi-arm branched amphiphilic scaffolds loaded with hydrophobic drugs
EP4071159B1 (en) 2016-08-02 2023-12-13 President and Fellows of Harvard College Crisscross cooperative self-assembly
JP6912876B2 (ja) * 2016-10-06 2021-08-04 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
CN107236106B (zh) * 2017-06-13 2020-01-07 青岛科技大学 含酰腙键的芳香族端羟基扩链剂、自修复聚氨酯及其制备方法
US10376468B2 (en) * 2017-12-05 2019-08-13 International Business Machines Corporation Block copolymers and self-assembling nanoparticles formed therefrom
CN108904446B (zh) * 2018-06-11 2021-05-11 中山大学 一种动脉斑块微环境响应的载药纳米胶束的制备方法及应用
JP7154568B2 (ja) * 2018-06-22 2022-10-18 国立大学法人福井大学 両親媒性高分子、およびその利用
US20220031849A1 (en) * 2018-10-22 2022-02-03 Takeda Pharmaceutical Company Limited Nanoparticle encapsulation to target g protein-coupled receptors in endosomes
WO2020210468A1 (en) 2019-04-10 2020-10-15 President And Fellows Of Harvard College Nucleic acid nanostructures crosslinked with oligolysine
KR102329966B1 (ko) * 2020-03-23 2021-11-23 전남대학교산학협력단 양친성 고분자 화합물, 이를 이용한 약물 전달체 및 종양 치료 시스템
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers
KR102418116B1 (ko) * 2020-10-08 2022-07-06 강원대학교산학협력단 양친매성 공중합체로 안정화된 산화 응답성 에멀젼
WO2023003384A1 (ko) 2021-07-21 2023-01-26 주식회사 삼양홀딩스 조직 수복용 분말 제형 및 이의 제조 방법, 및 이를 포함하는 조직 수복용 주사제 조성물
WO2025145010A1 (en) * 2023-12-29 2025-07-03 The University Of Chicago Amphiphilic block copolymers, polymersomes, and methods of use

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203577A (en) 1966-10-27 1970-08-26 Dunlop Co Ltd Improvements in or relating to the preparation of polymerized episulphides
CA992105A (en) 1970-03-26 1976-06-29 Exxon Research And Engineering Company Polythioethers formed by anionic ring opening of episulfides
JPS5835612B2 (ja) 1978-10-04 1983-08-03 テルモ株式会社 新規なブロック共重合体の製造方法
US4618400A (en) 1984-12-28 1986-10-21 Shell Oil Company Wastepaper deinking process
US4923924A (en) 1985-12-06 1990-05-08 Borg-Warner Chemicals, Inc. Thermoplastic impact modified polyamide-polyphenylene ether composition
US4732938A (en) 1985-12-06 1988-03-22 Borg-Warner Chemicals, Inc. Thermoplastic polyamide--polyphenylene ether compositions
CN1046741A (zh) 1988-04-30 1990-11-07 三井东圧化学株式会社 以多硫化物为基础的树脂，含有该树脂的塑料透镜以及制造该种透镜的方法
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5247041A (en) 1989-02-22 1993-09-21 Toray Industries, Inc. Thiol methacrylate or acrylate resin obtained by polymerizing a thiol methacrylate or acrylate compound
US5268305A (en) 1989-06-15 1993-12-07 Biocircuits Corporation Multi-optical detection system
US5330911A (en) 1989-09-28 1994-07-19 Board Of Regents, The University Of Texas System Surfaces having desirable cell adhesive effects
US5852182A (en) 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
EP0656888B1 (en) 1992-08-25 1998-01-07 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5502102A (en) 1994-08-09 1996-03-26 General Electric Company Epoxy modified blends of poly(arylenesulfide) and polyetherimide resins
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US5752974A (en) 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
FR2746035B1 (fr) 1996-03-15 1998-06-12 Microparticules de gel composite susceptibles d'etre utilisees comme vecteur(s) de principe(s) actif(s), l'un de leurs procedes de preparation et leurs applications
US5914182A (en) 1996-06-03 1999-06-22 Gore Hybrid Technologies, Inc. Materials and methods for the immobilization of bioactive species onto polymeric substrates
US6013855A (en) 1996-08-06 2000-01-11 United States Surgical Grafting of biocompatible hydrophilic polymers onto inorganic and metal surfaces
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6224903B1 (en) 1996-10-11 2001-05-01 Sequus Pharmaceuticals, Inc. Polymer-lipid conjugate for fusion of target membranes
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
ATE200030T1 (de) 1997-01-29 2001-04-15 Polymasc Pharmaceuticals Plc Pegylationsverfahren
JP2003526692A (ja) 1997-08-01 2003-09-09 サプラテック ファーマ インコーポレーテッド ポリヌクレオチド組成物
US5945457A (en) 1997-10-01 1999-08-31 A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science Process for preparing biologically compatible polymers and their use in medical devices
CN1195788C (zh) * 1997-10-03 2005-04-06 麦克罗梅德公司 具有可逆热胶凝性质的可生物降解低分子量三嵌段聚(丙交酯－共聚－乙交酯)聚乙二醇共聚物
US6884842B2 (en) 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
DK1053019T3 (da) 1998-01-07 2004-04-13 Debio Rech Pharma Sa Nedbrydelige heterobifunktionelle polyethylenglycolacrylater og geler og konjugater afledt derfra
JPH11335267A (ja) * 1998-05-27 1999-12-07 Nano Career Kk 水難溶性薬物を含有するポリマーミセル系
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
ES2632564T3 (es) 1999-02-01 2017-09-14 Eidgenössische Technische Hochschule Zürich Bio-materiales formados por reacción de adición nucleófila a grupos insaturados conjugados
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
GB9912077D0 (en) 1999-05-24 1999-07-21 Unilever Plc Polysiloxane block copolymers in topical cosmetic and personal care compositions
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6916488B1 (en) 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
JP3523821B2 (ja) * 2000-02-09 2004-04-26 ナノキャリア株式会社 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物
ES2390066T3 (es) * 2000-05-12 2012-11-06 Samyang Biopharmaceuticals Corporation Procedimiento para la preparación de micelas poliméricas mediante separación de fase de un copolímero en bloque
ES2386258T3 (es) 2000-06-02 2012-08-14 Eidgenössische Technische Hochschule Zürich Relaciones de adición conjugadas para la entrega controlada de compuestos farmacéuticamente activos
FR2809617B1 (fr) 2000-06-05 2002-07-12 Rhodia Chimie Sa Composition aqueuse bucco-dentaire antiplaque
US7465790B2 (en) * 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
CA2426692C (en) 2000-10-19 2011-01-25 Eidgenossische Technische Hochschule Zurich Block copolymers for multifunctional self-assembled systems
MXPA03008498A (es) 2001-03-20 2005-06-30 Univ Zuerich Procesamiento en dos fases de polimeros termosensibles para uso como biomateriales.
WO2003002096A1 (en) * 2001-06-28 2003-01-09 Wisconsin Alumni Research Foundation Methods and compositions for polyene antibiotics with reduced toxicity
US7226616B2 (en) * 2001-07-14 2007-06-05 Samyang Corporation Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug
US20040208844A1 (en) * 2001-08-01 2004-10-21 Francis Ignatious Products and drug delivery vehicles
MXPA04002554A (es) * 2001-09-18 2004-05-31 Univ Zuerich Metodos y aparatos para revestir superficies para reducir la adsorcion de proteinas y la adhesion celular y presentar ligandos.
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
CN1659233A (zh) 2002-04-09 2005-08-24 通用电气公司 热固性组合物、方法和制品
US20030215588A1 (en) 2002-04-09 2003-11-20 Yeager Gary William Thermoset composition, method, and article
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
US7521414B2 (en) * 2003-06-20 2009-04-21 The Regents Of The University Of California Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
SG113562A1 (en) * 2004-01-12 2005-08-29 Agency Science Tech & Res Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
JP2005298542A (ja) 2004-04-06 2005-10-27 Dainippon Ink & Chem Inc ブロックコポリマー及びその製造方法
US7495052B2 (en) 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US20060057215A1 (en) 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2006071769A1 (en) * 2004-12-28 2006-07-06 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060224095A1 (en) 2005-04-05 2006-10-05 University Of New Hampshire Biocompatible polymeric vesicles self assembled from triblock copolymers
US8173167B2 (en) * 2005-04-12 2012-05-08 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
DE112006000685B4 (de) 2005-04-13 2016-03-10 Sungkyunkwan University Foundation For Corporate Collaboration Temperatur- und pH-empfindliches Blockcopolymer und daraus hergestellte Polymerhydrogele
JP5329949B2 (ja) * 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
US20090214419A1 (en) * 2005-09-28 2009-08-27 The Trustees Of The University Of Pennsylvania Self-assembled biodegradable polymersomes
JP4259599B2 (ja) * 2005-10-05 2009-04-30 東京Ｃｒｏ株式会社 生体適合性ブロック共重合体、その用途および製造法
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
WO2007099660A1 (ja) * 2006-03-01 2007-09-07 The University Of Tokyo 核酸内包高分子ミセル複合体
CN101573141B (zh) * 2006-05-15 2016-05-04 麻省理工学院 用于功能性颗粒的聚合物
EP2087912B1 (en) * 2006-11-22 2017-05-10 The University of Tokyo Sirna carrier using disulfide-bridged polymeric micelle
WO2008070141A2 (en) * 2006-12-06 2008-06-12 Wisconsin Alumni Research Foundation Compositions for delivery of therapeutic agents
WO2009035771A1 (en) * 2007-09-12 2009-03-19 Boston Scientific Limited Embolization particles
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
EP2356228B1 (en) * 2008-11-25 2023-05-03 École Polytechnique Fédérale de Lausanne (EPFL) Block copolymers and uses thereof
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials

Also Published As

Publication number Publication date
JP6641423B2 (ja) 2020-02-05
US20200000936A1 (en) 2020-01-02
US20220168448A1 (en) 2022-06-02
EP2356228B1 (en) 2023-05-03
JP2020073678A (ja) 2020-05-14
US10335499B2 (en) 2019-07-02
EP2356228A4 (en) 2015-05-13
JP2015071762A (ja) 2015-04-16
EP2356228A1 (en) 2011-08-17
US20110223217A1 (en) 2011-09-15
JP2017002280A (ja) 2017-01-05
US20160256569A1 (en) 2016-09-08
JP5995939B2 (ja) 2016-09-21
US9271929B2 (en) 2016-03-01
JP6409020B2 (ja) 2018-10-17
JP2012509983A (ja) 2012-04-26
WO2010068432A1 (en) 2010-06-17
JP2018188642A (ja) 2018-11-29
US20250001005A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
JP6409020B2 (ja) ブロックコポリマーおよびその使用
JP5329949B2 (ja) 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
Vinogradov et al. Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells
EP3072506B1 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
JP5271715B2 (ja) ジスルフィド架橋高分子ミセルを用いた環境応答性ｓｉＲＮＡキャリア
WO2013162041A1 (ja) 核酸デリバリー用ユニット構造型医薬組成物
EP3299020A1 (en) Micelle composition for nucleic acid delivery using temperature-sensitive polymer and method for producing same
Leiske et al. How To Tune the Gene Delivery and Biocompatibility of Poly (2-(4-aminobutyl)-2-oxazoline) by Self-and Coassembly
WO2014084378A1 (ja) 環状ｒｇｄ配列含有ペプチドを含む抗癌剤
US20220118094A1 (en) Synthesis of biomimetic cell wall structure
US20250101175A1 (en) Star-shaped pasp-oligoamine derivatives
AU2007319836A1 (en) Efficient nuclear delivery of antisense oligonucleotides
WO2024147020A1 (en) Polymersomes for delivery of nucleic acid cargoes
Gary et al. Influence of Nano-Carrier Architecture on in Vitro siRNA Delivery Performance andin VivoBiodistribution: Polyplexesvs Micelleplexes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141024

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150918

R150 Certificate of patent or registration of utility model

Ref document number: 5814793

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250